🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "significant breakthrough" in the effort against increasingly resistant strains of the pathogen, according to health experts.

A Worldwide Public Health Issue

The sexually transmitted infection are escalating globally, with figures suggesting over 82 million new cases annually. Especially elevated rates are observed in the African continent and nations within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. In England, cases have hit a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune development in the reality of growing infection rates, escalating drug resistance and the very limited therapeutic options currently available.”

Health officials are particularly alarmed about the surge in drug-resistant strains. The World Health Organization has classified it as a "critical concern". A tracking program showed that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Treatment Options Secure Authorization

One new antibiotic, marketed under the name Nuzolvence, was approved by the US FDA in December for treating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Researchers believe that specific application of this new drug will help slow the emergence of superbugs.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This drug, which is also used to treat UTIs, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin stemmed from a innovative non-profit model for drug creation. The non-profit organisation GARDP worked alongside the drug firm its industry partner to see it through.

“This approval signifies a significant shift in the treatment of multidrug-resistant gonorrhoea, which previously has been evolving faster than medical innovation.”

Testing Data and Global Access

According to findings released by a major medical journal, the new drug successfully treated more than 90% of uncomplicated infections. This puts it on an equal footing with the typical regimen, which combines an injection and a pill. The research involved nearly 1,000 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, the non-profit has the rights to license and sell the drug in numerous regions with limited resources.

Clinicians on the front lines have expressed positive views. Having a single-dose, oral treatment such as this is described as a "revolutionary step" for public health efforts. This is viewed as essential to alleviate the strain of the disease for individuals and to stop the proliferation of untreatable gonorrhoea worldwide.